Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out
Acepodia chairman and co-founder Patrick Yang called cancer “the longest war America (has) ever fought.” So when he met Sonny Hsiao in 2016 and saw his “clever, very simple, elegant” approach to battling tumor cells, he was all in.
Four years and some very early positive results later, Yang and Hsiao have racked up another $109 million from investors to see their “antibody-cell conjugates” through the clinic. And while Yang says this isn’t a crossover round, he admitted that the company is “watching the capital climate” and could possibly file for an IPO next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
